Login to Your Account



Clavis' Phase III AML Study Delayed by Production Glitch

By Cormac Sheridan
BioWorld International Correspondent

Wednesday, January 18, 2012

Quality management problems at its contract manufacturer, Ben Venue Laboratories Inc., have forced Clavis Pharma ASA to slow recruitment in a Phase III trial of elacytarabine in late-stage acute myeloid leukemia (AML) and will result in a delay of one quarter in the reporting of its results.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription